PRIMARY STUDY

Phytocannabinoids as novel therapeutic agents in CNS disorders

Key Findings:  This review synthesizes preclinical and emerging clinical evidence showing that non-Δ⁹-THC phytocannabinoids such as CBD, CBG, THCV, and CBDV exert therapeutic effects in CNS disorders via diverse, non–CB receptor–limited mechanisms, highlighting their potential as next-generation, non-psychoactive cannabinoid-based medicines for conditions including epilepsy, neurodegeneration, affective disorders, and dysregulated feeding.